Successful TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for a Patient With Artemis Deficiency

J Pediatr Hematol Oncol. 2023 Mar 1;45(2):e285-e289. doi: 10.1097/MPH.0000000000002522. Epub 2023 Feb 6.

Abstract

Artemis deficiency is characterized by DNA double-strand breaks repairing dysfunction and increased sensitivity to ionizing radiation and alkylating reagents. We describe the first successful case of T-cell receptor [TCR]αβ/CD19-depleted hematopoietic cell transplantation [HCT] for Artemis deficiency in Japan. A 6-month-old Korean boy was diagnosed with Artemis-deficient severe combined immunodeficiency. He had no human leukocyte antigen (HLA)-matched sibling or unrelated donor. Therefore, TCRαβ/CD19-depleted HCT from his haploidentical mother was performed. Despite mixed chimerism in whole blood, T cells achieved complete donor chimerism 6 months after HCT. TCRαβ/CD19-depleted HCT could be an effective treatment for patients with radiation-sensitive severe combined immunodeficiency.

Publication types

  • Case Reports

MeSH terms

  • Antigens, CD19
  • Graft vs Host Disease* / etiology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Infant
  • Male
  • Receptors, Antigen, T-Cell, alpha-beta
  • Severe Combined Immunodeficiency* / genetics
  • T-Lymphocytes
  • Transplantation Conditioning
  • Unrelated Donors

Substances

  • Antigens, CD19
  • Receptors, Antigen, T-Cell, alpha-beta